Abrahamson Eye Institute, Cincinnati Children's Hospital Medical Center, , Cincinnati, Ohio, USA.
Br J Ophthalmol. 2014 Apr;98(4):513-8. doi: 10.1136/bjophthalmol-2013-304270. Epub 2014 Jan 23.
To assess the genotypic diversity in patients with Stargardt disease and to characterise epidemiological and genotypic predictors of phenotype.
Retrospective, cross-sectional study of 112 patients with Stargardt disease. We evaluated the correlation between age at presentation, best-corrected visual acuity (BCVA), and ABCA4 genotypes.
Mean age at presentation was 30 ± 16 years (range 6-78 years) for the 112 patients of 104 families. 98 of 90 families had a probable molecular diagnosis. We found that BCVA is not related to age of presentation in a linear or polynomial manner; that BCVA of patients presenting in the first decade was significantly worse than those presenting in later decades (p=0.04); that patients who harboured two or more mutations presented earlier and had worse BCVA than those with no or 1 mutation identified by any method of testing (n=112, p=3.29 × 10(-6)) or by full sequencing (n=32, p=0.02); that 16 patients with c.5882G>A allele demonstrated better BCVA than the remaining patients (p=0.01); and that 10 patients with the c.5461-10T>C mutation presented earlier (p=0.02 × 10(-5)) and had more severe disease.
Epidemiological and genotypical findings portend visual prognosis in patients with Stargardt disease. Select sequence variations in ABCA4 may confer a specific phenotype. The present data will help in assessing patients for emerging therapies.
评估斯塔加特病患者的基因型多样性,并描述表型的流行病学和基因型预测因子。
回顾性、横断面研究了 112 例斯塔加特病患者。我们评估了发病年龄、最佳矫正视力(BCVA)和 ABCA4 基因型之间的相关性。
104 个家系的 112 例患者的平均发病年龄为 30 ± 16 岁(范围 6-78 岁)。90 个家系中有 98 个有明确的分子诊断。我们发现,BCVA 与发病年龄之间不是线性或多项式关系;发病年龄在第一个十年的患者的 BCVA 明显比发病年龄在以后十年的患者差(p=0.04);携带两个或两个以上突变的患者比任何检测方法(n=112,p=3.29 × 10(-6)) 或全序列分析(n=32,p=0.02)确定无突变或只有 1 个突变的患者发病更早,BCVA 更差;携带 c.5882G>A 等位基因的 16 例患者的 BCVA 比其余患者好(p=0.01);10 例携带 c.5461-10T>C 突变的患者发病更早(p=0.02 × 10(-5)),疾病更严重。
斯塔加特病患者的流行病学和基因型发现预示着视力预后。ABCA4 中的某些序列变异可能导致特定的表型。目前的数据将有助于评估患者接受新兴疗法的情况。